Lack of expression of TUBB3 characterizes both BCL2-positive and BCL2-negative follicular lymphoma

Zamò, Alberto; Erdini, Francesco; Malerba, Giovanni; Chilosi, Marco

doi:10.1038/modpathol.2013.182

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Percentage of TUBB3 cancers in previous studies (blue dots) as compared to the results of our study (red dots). Figures [1], 29 [2], 4 [3], 30 [4], 31,32 [5], 32,33 [6], 33 [7], 5,12,18,34–42 [8], 19 [9], 19 [10], 15 [12], 15 [13], 15 [14], 15,19,43 [15], 44 [16], 19,31 [17], 45,46 [18], 19 [19], 5,19,47–49 [20], 50 [21], 19 [22], 19,51 [23], 6,19 [24], 52–54 [25], 7 [26], 7 [27], 7 [28], 19,20 [29], 55 [30], 56 [31], 8 [32], 8 [33], 8 [34], 8 [35], 54,57 and [36]. 39 …”

Section: Discussionmentioning

confidence: 99%

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers

et al. 2017

View full text Add to dashboard Cite

Microtubules are multifunctional cytoskeletal proteins that are involved in crucial cellular roles including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III beta-tubulin (βIII-tubulin, also known as TUBB3) is a microtubule protein, normally expressed in cells of neuronal origin. Its expression was also reported in various other tumor types, such as several types of lung cancer, ovarian cancer, and esophageal cancer. TUBB3 is of clinical relevance as overexpression has been linked to poor response to microtubule-targeting anti-cancer drugs such as taxanes. To systematically investigate the epidemiology of TUBB3 expression in normal and neoplastic tissues, we used tissue microarrays for analyzing the immunohistochemically detectable expression of TUBB3 in 3911 tissue samples from 100 different tumor categories and 76 different normal tissue types. At least 1 tumor with weak expression could be found in 93 of 100 (93%) different tumor types, and all these 93 entities also had at least 1 tumor with strong positivity. In normal tissues, a particularly strong expression was found in neurons of the brain, endothelium of blood vessels, fibroblasts, spermatogenic cells, stroma cells, endocrine cells, and acidophilic cells of the pituitary gland. In tumors, strong TUBB3 expression was most frequently found in various brain tumors (85%-100%), lung cancer (35%-80%), pancreatic adenocarcinoma (50%), renal cell carcinoma (15%-80%), and malignant melanoma (77%). In summary, these results identify a broad spectrum of cancers that can at least sporadically express TUBB3. Testing of TUBB3 in cancer types eligible for taxane-based therapies could be helpful to identify patients who might best benefit from this treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers

et al. 2017

View full text Add to dashboard Cite

show abstract

“…As it may be difficult to diagnose BCL2-negative FL, other diagnostic markers have been investigated. For example, Masir et al (16) reported that a rabbit monoclonal BCL2 antibody (E17) facilitated the diagnosis of BCL2-negative FLs, whereas Zamo et al (17) reported the lack of TUBB3 expression in BCL2-negative FLs. The present study hypothesized that PCDHGA3 is a useful diagnostic marker for all cases of FL, as PCDHGA3 expression was observed irrespective of BCL2 status.…”

Section: Discussionmentioning

confidence: 99%

Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth

Zhang

Takata

Cui

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Protocadherin genes (PCDHs) have been suggested to act as tumor suppressor genes in various tumor types. Previous studies have demonstrated the upregulation of certain PCDH-γ subfamily genes in nodal and duodenal follicular lymphoma (FL) using gene expression analyses. However, the mechanisms and associated molecular function of PCDH-γ subfamily gene upregulation in FL remain to be elucidated. The present study examined the expression of PCDHGA3, an upregulated PCDH-γ gene subfamily member, in B-cell lymphoma 2 (BCL2)-positive and -negative FL, and evaluated its association with tumor cell proliferation in an FL-derived cell line. Immunohistochemical analysis demonstrated that the majority of FL grade 1–2 samples (19/20; 95%) and over half of grade 3A FL samples (5/9; 56%) were PCDHGA3-positive, whereas only 1/17 reactive lymphoid hyperplasia samples was positive. Notably, this positivity was widely observed in samples of BCL2-negative FL (13/15; 87%) and FL with diffuse area (10/10; 100%). The FL-derived cell line FL18 exhibited strong PCDHGA3 expression, similar to the patient samples, and its proliferation was suppressed by PCDHGA3 gene knockdown. Genes expressed concomitantly with PCDHGA3 were selected from gene expression data, and TNFRSF6B, a member of the tumor necrosis factor receptor superfamily, was among the top five most strongly correlated genes. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance. In conclusion, the results of the present study indicated that PCDHGA3 was expressed in FL irrespective of BCL2 status and grading and was associated with cell proliferation. Further studies involving molecular genetic analyses are required to elucidate the mechanisms underlying the activity of PCDHGA3 in FL.

show abstract

Lack of expression of TUBB3 characterizes both BCL2-positive and BCL2-negative follicular lymphoma

Cited by 2 publications

References 18 publications

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers

Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth

Contact Info

Product

Resources

About